Barinthus Bio reports $142M cash, extends runway to Q4 2025, details 2024 milestones

Barinthus Biotherapeutics plc.

Preliminary cash and equivalents: $142M as of Dec 31, 2023; ~38.6M ordinary shares outstanding.
Cash runway extended from Q2 to Q4 2025 by deferring VTP-1100 IND in HPV cancer and phasing manufacturing.
H1 2024: initiate Phase 1 trial of VTP-1000 in Celiac Disease; final Phase 1b/2 VTP-200 (HPV) data.
H1 2024: interim data from HBV003 (Phase 2b VTP-300 dosing) and AB-729-202 (VTP-300 + imdusiran) trials.
H2 2024: interim data from third arm of AB-729-202 adding nivolumab to VTP-300 and imdusiran.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.